Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. Show More...

  • Website http://www.axsome.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 105.16 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -0.17 -0.47 -1.02 -1.42 -1.27 -1.15 -2.01 -2.57
    Dividends USD
    Payout Ratio % *
    Shares Mil 13.0 13.0 12.0 19.0 23.0 27.0 34.0 35.0
    Book Value Per Share * USD 0.2 1.47 0.66 0.02 0.18 4.21
    Free Cash Flow Per Share * USD -0.4 -0.86 -1.28 -1.04 -1.18
    Return on Assets % -103.3 -245.74 -40.72 -62.33 -78.47 -121.59 -57.94 -74.63
    Financial Leverage (Average) 1.06 1.77 2.13 16.4 1.23 1.27
    Return on Equity % -48.84 -79.99 -151.19 -350.78 -76.08 -103.95
    Return on Invested Capital % -53.07 -61.88 -95.25 -172.98 -64.99 -84.69
    Interest Coverage -5.62 -204.41 -20.6 -26.47 -54.14
    Current Ratio 0.51 2.82 18.63 5.3 2.9 1.4 8.99 7.57
    Quick Ratio 0.51 2.69 18.25 5.11 2.79 1.29 8.98 7.56
    Debt/Equity 0.44 0.4 3.85 0.1 0.1